crabseed3
About
Tipifarnib boosts anti-EGFR exercise regarding cetuximab in non-HRas mutated head and neck squamous mobile carcinoma cancers (HNSCC).
Tipifarnib boosts anti-EGFR exercise regarding cetuximab in non-HRas mutated head and neck squamous mobile carcinoma cancers (HNSCC).